YISHENG BIOPHARMA
Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.
YISHENG BIOPHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2002-01-01
Address:
Beijing, Beijing, China
Country:
China
Website Url:
http://www.yishengbio.com
Total Employee:
501+
Status:
Active
Contact:
+86 400-659-1155
Email Addresses:
[email protected]
Total Funding:
170 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Content Delivery Network Apache Wordpress Plugins Euro ReCAPTCHA
Similar Organizations
Hygea Medical Technology
Hygea Medical Technology is a oncology-focused biopharma company.
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Current Employees Featured
Founder
Investors List
CBC Group
CBC Group investment in Venture Round - Yisheng Biopharma
Epiphron Capital
Epiphron Capital investment in Series B - Yisheng Biopharma
F-Prime Capital
F-Prime Capital investment in Series B - Yisheng Biopharma
Superstring Capital
Superstring Capital investment in Series B - Yisheng Biopharma
Haitong International Securities Group
Haitong International Securities Group investment in Series B - Yisheng Biopharma
MSA Capital
MSA Capital investment in Series B - Yisheng Biopharma
OrbiMed
OrbiMed investment in Series B - Yisheng Biopharma
Adjuvant Capital
Adjuvant Capital investment in Series B - Yisheng Biopharma
Hillhouse Capital Group
Hillhouse Capital Group investment in Series B - Yisheng Biopharma
Oceanpine Capital
Oceanpine Capital investment in Series B - Yisheng Biopharma
